Begin main content

Lanreotide for the Treatment of Neuroendocrine Tumours: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Last updated: August 21, 2017
Project Number: RC0913-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of lanreotide for the treatment of neuroendocrine tumours in adults?
  2. What is the cost-effectiveness of lanreotide for the treatment of neuroendocrine tumours in adults?
  3. What are the evidence-based guidelines associated with lanreotide for the treatment of neuroendocrine tumours in adults?

Key Message

Evidence from the included studies1,9,10 suggests that lanreotide autogel has antiproliferative activity and is effective at controlling symptoms of carcinoid syndrome (CS), with a favorable safety and tolerability profile in patients with NETs. One randomized controlled trial (RCT) in the included systematic review (SR),9 reported that the overall median progression free survival (PFS) of lanreotide autogel dosed at 120 mg every four weeks was 32.8 months in patients with well-differentiated or moderately differentiated G1 of G2 GEP-NETs compared with 18 months of placebo. A subgroup of patients with pancreatic NETS (pNETs) in that study had a median PFS of 29.7 months. One small (n=30) non-randomized study1 reported that the 5-year overall survival (OS) was 87.5% with lanreotide autogel versus 65.6% with octreotide. One RCT10 found that the odds of success or partial success in treating diarrhea associated with CS were significantly higher with lanreotide than with placebo (OR = 2.4; 95% CI: 1.1, 5.3). One non-randomized study,11 found that the majority of patients treated with lanreotide autogel were either ‘completely’ or ‘rather satisfied’ with the control of diarrhea (76%) or flushing episodes (73%). One economic evaluation12 conducted in Europe estimated that the overall annual cost-savings for using lanreotide autogel versus octreotide long-acting release (LAR) to treat patients with acromegaly or NETs ranged from EUR 1.9 million to 7.07 million, with the savings driven by lower price, reduced administration time, and lower risk of clogging associated with lanreotide autogel. The literature search did not identify any evidence-based guidelines with recommendations specific for the use of lanreotide in the treatment of NETs.